Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BTLA biology in cancer: from bench discoveries to clinical potentials
Anna Andrzejczak, Lidia Karabon
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 17

Showing 17 citing articles:

Immune checkpoint inhibitors: breakthroughs in cancer treatment
Xueqing Kong, Jinyi Zhang, Shuwei Chen, et al.
Cancer Biology and Medicine (2024), pp. 1-11
Open Access | Times Cited: 20
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Md Aslam Hossain
International Immunopharmacology (2024) Vol. 143, pp. 113365-113365
Closed Access | Times Cited: 8
Integrated Analysis of Single-Cell and Bulk RNA Data Reveals Complexity and Significance of the Melanoma Interactome
Michael J. Diaz, Jasmine T. Tran, Arthur M. Samia, et al.
Cancers (2025) Vol. 17, Iss. 1, pp. 148-148
Open Access
Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy
Shay Tzaban, Otto Stern, Elad Zisman, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Immunological Network Signature of Naïve Non-Oncogene-Addicted Non-Small Cell Lung Cancer Patients Treated with Anti-PD1 Therapy: A Pilot Study
Pasquale Sibilio, Ilaria Grazia Zizzari, Alain Gelibter, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 922-922
Open Access
Recent advances in oncolytic virus combined immunotherapy in tumor treatment
Xiaoli Zhou, Shunfeng Hu, Xin Wang
Genes & Diseases (2025), pp. 101599-101599
Open Access
BTLApromoter hypomethylation correlates with enhanced immune cell infiltration, favorable prognosis, and immunotherapy response in melanoma
Minglei Yang, Chenxi Zheng, Miao Yu, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e009841-e009841
Open Access
Epigenetic regulators combined with tumour immunotherapy: current status and perspectives
Huan Zhang, Yuepeng Pang, Ling Yi, et al.
Clinical Epigenetics (2025) Vol. 17, Iss. 1
Open Access
BTLA agonist attenuates Th17-driven inflammation in a mouse model of steroid-resistant asthma
Christine Quach, Xin Li, Pedram Shafiei-Jahani, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Development and evaluation of an ovarian cancer prognostic model based on adaptive immune-related genes
H. Shi, Lijuan Li, Linying Zhou, et al.
Medicine (2025) Vol. 104, Iss. 14, pp. e42030-e42030
Open Access
Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes
Ornella Franzese
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12848-12848
Open Access | Times Cited: 3
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities
Jing Zhang, Xiaoping Zeng, Qiji Guo, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Targeting BTLA with the peptide inhibitor HVEM(14-39) – A new way to restore the activity of T cells in melanoma
Karolina Wojciechowicz, Katarzyna Kuncewicz, Jacek Rutkowski, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116675-116675
Open Access | Times Cited: 1
Effect of HVEM/CD160 Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival
Anna Andrzejczak, Bartosz Małkiewicz, Krzysztof Tupikowski, et al.
(2024)
Open Access | Times Cited: 1
The Immune Checkpoint BTLA in Oral Cancer: Expression Analysis and Its Correlation to Other Immune Modulators
Jutta Ries, Leah Trumet, Alina Hahn, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6601-6601
Open Access
Effect of HVEM/CD160 Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival
Anna Andrzejczak, Bartosz Małkiewicz, Krzysztof Tupikowski, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6860-6860
Open Access
Proteomic Investigation of Immune Checkpoints and Some of Their Inhibitors
Marco Agostini, Pietro Traldi, Mahmoud Hamdan
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9276-9276
Open Access
Elevated expression of BTLA predicts poor prognosis and is associated with immune infiltration in glioma
Dongjie Zhou, Lirui Dai, Ao Shen, et al.
Asian Journal of Surgery (2024)
Open Access
Page 1

Scroll to top